Vilo Research Group Inc, United States

Registration Status: Completed

Objective: Vilo Research Group Inc. is a clinical research network in Greater Houston, Texas. Although primarily a clinical research network, Vilo Research Group also plays a pivotal role in biobanking. Established by Dr. Jorge Mendez in 2017, Vilo Research Group contributes to the collection, storage, and analysis of biospecimens for research purposes, aligning with its commitment to advancing medical knowledge and improving patient outcomes, with its dedication to providing accurate data and Biospecimens, partners with different entities to enhance access to minority populations. This collaboration aims to foster interdisciplinary research methodologies and collaborative partnerships, facilitating the connection between biomedical researchers and community healthcare actors. Through innovative approaches like implementing remote collaboration in virtual patient platforms, VRG strives to improve patient outcomes and advance medical science.

Registered Biobank Name	Vilo Research Group Inc
Biobank Leader	Jorge H. Mendez
Country	United States
Email for biobank inquiries	viloresearch@gmail.com
Principal Investigator	Jorge H. Mendez, Luis E. Zepeda, Elvis Massip
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).